Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $11.25.

A number of equities analysts have weighed in on MRKR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. HC Wainwright started coverage on Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, Zacks Research cut Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th.

Marker Therapeutics Price Performance

Shares of MRKR opened at $1.26 on Wednesday. The company has a market cap of $21.00 million, a PE ratio of -1.48 and a beta of 1.42. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.31. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.17. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%. The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million. Analysts expect that Marker Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently modified their holdings of MRKR. NewEdge Advisors LLC bought a new position in shares of Marker Therapeutics in the fourth quarter valued at about $222,000. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter worth about $60,000. Boyer Financial Services Inc. bought a new stake in shares of Marker Therapeutics during the 4th quarter worth about $57,000. Two Sigma Investments LP acquired a new position in Marker Therapeutics in the 3rd quarter valued at about $33,000. Finally, XTX Topco Ltd grew its stake in Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares during the last quarter. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.